Boai NKY Medical will hold 4,922,544 shares, representing 4.1 per cent of shares and votes in NeoDynamics, after the transaction.
For further information, please contact:
Anna Eriksrud, CEO NeoDynamics AB, phone +46708 444966 or e-mail anna.eriksrud@neodynamics.com (anna.eriksrud@neodynamics.se)
CFO Aaron Wong, phone +46 735 972 011 or e-mail aaron.wong@neodynamics.com
About NeoDynamics
NeoDynamics AB (publ) is a Swedish Medical Technology Company dedicated to advancing diagnosis and care of breast cancer. The company's first product NeoNavia®, a new innovative pulse biopsy system for ultrasound guided tissue sampling, is currently being introduced to the market. The biopsy system is built on a patented pulse technology, based on research at the Karolinska Institutet in Sweden. NeoNavia has received CE approval and is bing marketed in UK, Germany, and Sweden. The pulse biopsy system has been used for tissue sampling in breast and axilla in over 500 patients. NeoDynamic's share is listed on Nasdaq First North Growth Market Stockholm (ticker: NEOD). The company's Certified Adviser is Redeye AB, e-mail address: certifiedadviser@redeye.seand telephone number +46 8 121 576 90.